Overview

Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus

Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Chemoprevention therapy is the use of drugs to try and prevent the development or recurrence of cancer. It is not known whether eflornithine is effective in preventing cancer in patients with Barrett's esophagus. PURPOSE: Randomized double-blinded phase II trial to study the effectiveness of eflornithine in preventing cancer in patients with Barrett's esophagus.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center
University of Michigan Rogel Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Eflornithine